T-cell redirecting therapies with gene-engineered CAR T-cells and T-cell engaging bispecific antibodies (bsAb) are showing promising results in clinical trials. To guide precision immunotherapy, other factors should also be taken into consideration, including greater availability of immune targets and compounds with different modes of action during the development of new biomarkers, and determinants of response and resistance to a specific regimen.
In this technical session, Creative Biolabs invited Dr. Bruno Paiva to give us a clearer understanding of novel immunotherapies and the combined methods to be applied in the research of tumorigenesis and drug development.
Key webinar highlights:
Recognizing the “friend or foe” relationship between (blood) cancer and immunityLeveraging on the immunotherapies for malignant and nonmalignant (hematological) tumorsNeed for next-generation immune monitoring
Go to Event Website Advertisements
Similar events
International Conference on Agriculture, forestry, Biotechnology and Food Science (ICAFBFS) 6th International Conference on Agriculture, Biotechnology, Science and Engineering 5th International Conference on Biomedical, Biopharma and Clinical Research 6th International Conference on Otolaryngology and ENT 
LSX World Congress, London May 2023 – Biotechnology, Medical Devices, Digital Health Investment 
5th Annual MarketsandMarkets Next Gen Microbiome and Probiotics Conference, San Diego, USA